GLP-1 Medications and Brain Health: Can They Improve Memory and Cognitive Function
The Wegovy pill, approved by the MHRA in June 2026, is the first oral GLP-1 weight loss tablet in the UK and contains the same active ingredient, semaglutide, as the Wegovy injection
Here, we further develop this technology for improved prolonged release of both Sema and tirzepatide (TZP)

The findings established Ipamorelin's defining characteristic: Growth hormone Ipamorelin produced dose-dependent GH release comparable to GHRP-6 Cortisol No significant cortisol elevation was observed with Ipamorelin, while GHRP-2 and GHRP-6 produced measurable cortisol increases Prolactin No significant prolactin elevation at GH-effective concentrations ACTH No significant ACTH stimulation, contrasting with the adrenocorticotropic effects of other GHRPs GHRP Selectivity Comparison (Preclinical Data) Compound GH Release Cortisol Effect Prolactin Effect ACTH Effect Ipamorelin Dose-dependent Minimal / none Minimal / none Minimal / none GHRP-2 Dose-dependent Moderate increase Moderate increase Moderate increase GHRP-6 Dose-dependent Moderate increase Moderate increase Moderate increase Hexarelin Strong Significant increase Significant increase Significant increase Data adapted from Raun et al

Conclusion Dizziness on a GLP1 medication often reflects a combination of lower food intake, hydration changes, blood pressure shifts, or glucose changes
The main differences across comparison categories are: Mechanism of Action: advantage goes to MariTide